Return to Listing

1 result(s) for

PI Name Protocol # Title
Rebecca Silbermann STUDY00021440 A Phase I Study to Evaluate the Pharmacokinetics and Safety of belantamab mafodotin Monotherapy in Participants with Relapsed and/or Refractory Multiple Myeloma (RRMM) Who Have Normal and Varying Degrees of Impaired Renal Function (DREAMM 12)

You may also qualify for Phase 1 Program trials.

For more information:
Call: 503-494-1080